Gossamer Bio Phase 2 SHIFT-UC trial of GB004 misses primary endpoint; study terminated

Gossamer Bio, Inc.

Phase 2 trial of GB004 in mild-to-moderate active UC failed primary endpoint at week 12 (15.4% QD, 22.5% BID vs. placebo 17.9%).
No meaningful differences on secondary endpoints; Gossamer terminates treat-through and open-label extension portions.
Preliminary cash, cash equivalents, and marketable securities ~$272M as of March 31, 2022 (unaudited).
Target enrollment of 80 patients reached in Phase 2 TORREY trial of seralutinib in PAH; topline results expected Q4 2022.
Anticipates initiation of Phase 1b/2 STAR CNS trial of GB5121 in primary CNS lymphoma in late Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.